Literature DB >> 16610042

Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature.

Peter Laszlo Lakatos1, Sandor Fekete, Margit Horanyi, Simon Fischer, Margit E Abonyi.   

Abstract

An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and non-Hodgkin lymphoma (NHL) has been suggested. However, a causative role of HCV in these conditions has not been established. The authors report a case of a 50 year-old woman with chronic hepatitis C (CHC) who has been followed up since 1998 due to a high viral load, genotype 1b and moderately elevated liver function tests (LFTs). Laboratory data and liver biopsy revealed moderate activity (grade: 5/18, stage: 1/6). In April 1999, one-year interferon therapy was started. HCV-RNA became negative with normalization of LFTs. However, the patient relapsed during treatment. In September 2002, the patient was admitted for chronic back pain. A CT examination demonstrated degenerative changes. In March 2003, multiple myeloma was diagnosed (IgG-kappa, bone ma-rrow biopsy: 50% plasma cell infiltration). MRI revealed a compression fracture of the 5th lumbar vertebral body and an abdominal mass in the right lower quadrant, infiltrating the canalis spinalis. Treatment with vincristine, adriamycin and dexamethasone (VAD) was started and bisphosphonate was administered regularly. In January 2004, after six cycles of VAD therapy, the multiple myeloma regressed. Thalidomide, as a second line treatment of refractory multiple myeloma (MM) was initiated, and followed by peginterferon-alpha2b and ribavirin against the HCV infection in June. In June 2005, LFTs returned to normal, while HCV-RNA was negative, demonstrating an end of treatment response. Although a pathogenic role of HCV infection in malignant lymphoproliferative disorders has not been established, NHL and possibly MM may develop in CHC patients, supporting a role of a complex follow-up in these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16610042      PMCID: PMC4087667          DOI: 10.3748/wjg.v12.i14.2297

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  [Hepatitis C virus infection and B-cell non-Hodgkin's lymphoma].

Authors:  B Gasztonyi; A Pár; A Szomor; A Nagy; L Kereskai; H Losonczy; L Pajor; M Horanyi; G Mózsik
Journal:  Orv Hetil       Date:  2000-12-03       Impact factor: 0.540

2.  Hepatitis C virus infection and new association with extrahepatic disease: multiple myeloma.

Authors:  M Montella; A Crispo; F Russo; D Ronga; V Tridente; M Tamburini
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

3.  T(14;18) translocation in chronic hepatitis C virus infection.

Authors:  A L Zignego; F Giannelli; M E Marrocchi; A Mazzocca; C Ferri; C Giannini; M Monti; P Caini; G L Villa; G Laffi; P Gentilini
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

Review 4.  Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma.

Authors:  F Mizorogi; J Hiramoto; A Nozato; Y Takekuma; K Nagayama; T Tanaka; K Takagi
Journal:  Intern Med       Date:  2000-02       Impact factor: 1.271

5.  Ribavirin in the treatment of hepatitis C.

Authors:  Margit E Abonyi; Peter L Lakatos
Journal:  Anticancer Res       Date:  2005 Mar-Apr       Impact factor: 2.480

6.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia, multiple myeloma and chronic lymphocytic leukemia.

Authors:  S Gharagozloo; J Khoshnoodi; F Shokri
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

7.  Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia.

Authors:  Charles S Rabkin; Beatriz H Tess; Roberta E Christianson; William E Wright; David J Waters; Harvey J Alter; Bea J Van Den Berg
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

8.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

9.  [Activation of the nuclear factor kappa B--key role in oncogenesis? Chronic hepatitis C virus infection and lymphomagenesis].

Authors:  Beáta Gasztonyi; Alajos Pár; Katalin Kiss; László Kereskai; Arpád Szomor; József Szeberényi; László Pajor; Gyula Mózsik
Journal:  Orv Hetil       Date:  2003-05-04       Impact factor: 0.540

10.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

View more
  4 in total

1.  Nodular liver lesions involving multiple myeloma: a case report and literature review.

Authors:  Xiao-Ning Wu; Xin-Yan Zhao; Ji-Dong Jia
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

2.  Successful Chemotherapy Following Autologous Stem Cell Transplantation in Multiple Myeloma and Multi-organ Dysfunction with Infiltration of Eosinophils: A Case Report.

Authors:  Ho Sup Lee; Lee Chun Park; Seong Hoon Shin; Sang Uk Lee; Hee Kyung Chang; Bang Huh; Gyoo Sik Jung; Mi Hyang Kim; Yang Soo Kim
Journal:  Cancer Res Treat       Date:  2011-09-30       Impact factor: 4.679

Review 3.  Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy.

Authors:  Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2016-08-10

4.  Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.

Authors:  Alba Rodríguez-García; María Linares; María Luz Morales; Sophie Allain-Maillet; Nicolas Mennesson; Ricardo Sanchez; Rafael Alonso; Alejandra Leivas; Alfredo Pérez-Rivilla; Edith Bigot-Corbel; Sylvie Hermouet; Joaquín Martínez-López
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.